Lactylation-driven MVP upregulation boosts immunotherapy resistance by inhibiting PD-L1 degradation in hepatocellular carcinoma
Journal for ImmunoTherapy of Cancer · 2025-09 · 13 (9) · e012230
DOI: 10.1136/jitc-2025-012230 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 21.09.2025. Verfasst von Shuang Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, B7-H1 Antigen, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: China Postdoctoral Science Foundation, Natural Science Foundation of Jiangsu Province, Clinical Frontier Technology Project of the Jiangsu Key Research and Development.
Abstract (Originalsprache)
Background
Hepatocellular carcinoma (HCC) is a prevalent malignancy and the third leading cause of cancer-related mortality worldwide. Immune checkpoint inhibitors (ICIs) have emerged as first-line therapies for advanced HCC, substantially improving clinical outcomes. However, resistance to ICIs remains a major therapeutic challenge. Lactylation, a recently identified post-translational modification, has been implicated in tumor progression, although its role in ICIs resistance in HCC remains unclear.
Methods
Cytotoxicity assays, flow cytometry and orthotopic HCC mouse model were used to evaluate the effects of lactylation in remodeling the immune microenvironment. Chromatin immunoprecipitation sequencing and RNA sequencing were employed to identify lactylation-regulated gene profiles. Programmed cell death-ligand 1 (PD-L1) protein degradation was assayed by cycloheximide-chase analysis and ubiquitination assay. Interactions between major vault protein (MVP) and β-transducin repeat-containing protein (β-TrCP) were analyzed by co-immunoprecipitation experiments. Site-directed mutagenesis and truncation mutants were designed to determine binding sites of MVP-β-TrCP complex.
Results
Elevated lactylation correlates with poor prognosis and ICIs resistance in patients with HCC. Inhibition of lactylation enhances CD8 + T-cell infiltration and cytokine production. Multiomics analyses identify MVP as a lactylation-regulated factor that suppresses CD8 + T cell-mediated antitumor immunity. Elevated MVP expression is associated with resistance to checkpoint blockade therapy. Mechanistic studies reveal that histone lactylation-induced MVP upregulation stabilizes PD-L1 by preventing β-TrCP-mediated proteasomal degradation. Pharmacological inhibition of lactylation restores ICIs sensitivity in orthotopic HCC mouse models.
Conclusions
Our findings demonstrate that histone lactylation promotes ICIs resistance via MVP-dependent PD-L1 stabilization. Therefore, targeting lactylation in combination with programmed cell death protein-1/PD-L1 blockade offers a promising strategy to overcome immunotherapy resistance in HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.
- Department of Urology, Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.
- Sun Yat-sen University Cancer Center, Guangzhou, China.
- Department of Colorectal Surgery, Hunan Cancer Hospital, Changsha, Hunan, China.
- Department of Tumor Biological Treatment, Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.
- Department of Tumor Biological Treatment, Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China jiangjingting@suda.edu.cn.
Förderung
- China Postdoctoral Science Foundation
- Natural Science Foundation of Jiangsu Province
- Clinical Frontier Technology Project of the Jiangsu Key Research and Development
- Provincial-level Talent Program for National Center of Technology Innovation for Biopharmaceuticals
- National Natural Science Foundation Program of China
- Leading Innovative Talents of Changzhou
- Natural Science Research of Jiangsu Higher Education Institutions of China
Zitieren
APA
Liu, S., Pan, Y., Liu, W., Bu, X., Shao, R., Wang, Q., Wu, J., Wu, C., Hu, W., Xu, J., Wu, C., & Jiang, J. (2025). Lactylation-driven MVP upregulation boosts immunotherapy resistance by inhibiting PD-L1 degradation in hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer, 13(9), e012230. https://doi.org/10.1136/jitc-2025-012230
Vancouver
Liu S, Pan Y, Liu W, Bu X, Shao R, Wang Q, et al. Lactylation-driven MVP upregulation boosts immunotherapy resistance by inhibiting PD-L1 degradation in hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer. 2025;13(9):e012230. doi:10.1136/jitc-2025-012230
BibTeX
@article{Liu2025,
author = {Liu, Shuang and Pan, Yihui and Liu, Wenjian and Bu, Xiaoyun and Shao, Ruonan and Wang, Qi and Wu, Jun and Wu, Chen and Hu, Wenwei and Xu, Jun and Wu, Changping and Jiang, Jingting},
title = {Lactylation-driven MVP upregulation boosts immunotherapy resistance by inhibiting PD-L1 degradation in hepatocellular carcinoma},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2025},
volume = {13},
number = {9},
pages = {e012230},
doi = {10.1136/jitc-2025-012230}
}
EUVIMED